Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
Identifieur interne : 002925 ( Main/Corpus ); précédent : 002924; suivant : 002926Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
Auteurs : Alberto Albanese ; Ubaldo Bonuccelli ; Christine Brefel ; K. Ray Chaudhuri ; Carlo Colosimo ; Tobias Eichhorn ; Eldad Melamed ; Pierre Pollak ; Teus Van Laar ; Mario ZappiaSource :
- Movement Disorders [ 0885-3185 ] ; 2001-03.
English descriptors
- KwdEn :
Abstract
Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1069
Links to Exploration step
ISTEX:3638D905253CBADE5F33953F6B488F265CEAEE7ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name><affiliation><mods:affiliation>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation><mods:affiliation>Clinica Neurologica, Università di Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name><affiliation><mods:affiliation>Department of Neurology, King's College Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name><affiliation><mods:affiliation>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Service de Neurologie, Université J. Fourier, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation><mods:affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name><affiliation><mods:affiliation>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3638D905253CBADE5F33953F6B488F265CEAEE7E</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1069</idno><idno type="url">https://api.istex.fr/document/3638D905253CBADE5F33953F6B488F265CEAEE7E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002925</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><author><name sortKey="Albanese, Alberto" sort="Albanese, Alberto" uniqKey="Albanese A" first="Alberto" last="Albanese">Alberto Albanese</name><affiliation><mods:affiliation>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name><affiliation><mods:affiliation>Clinica Neurologica, Università di Pisa, Pisa, Italy</mods:affiliation></affiliation></author><author><name sortKey="Brefel, Christine" sort="Brefel, Christine" uniqKey="Brefel C" first="Christine" last="Brefel">Christine Brefel</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chaudhuri, K Ray" sort="Chaudhuri, K Ray" uniqKey="Chaudhuri K" first="K. Ray" last="Chaudhuri">K. Ray Chaudhuri</name><affiliation><mods:affiliation>Department of Neurology, King's College Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation><mods:affiliation>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Eichhorn, Tobias" sort="Eichhorn, Tobias" uniqKey="Eichhorn T" first="Tobias" last="Eichhorn">Tobias Eichhorn</name><affiliation><mods:affiliation>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation><mods:affiliation>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Service de Neurologie, Université J. Fourier, Grenoble, France</mods:affiliation></affiliation></author><author><name sortKey="Van Laar, Teus" sort="Van Laar, Teus" uniqKey="Van Laar T" first="Teus" last="Van Laar">Teus Van Laar</name><affiliation><mods:affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Zappia, Mario" sort="Zappia, Mario" uniqKey="Zappia M" first="Mario" last="Zappia">Mario Zappia</name><affiliation><mods:affiliation>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-03">2001-03</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="201">201</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3638D905253CBADE5F33953F6B488F265CEAEE7E</idno><idno type="DOI">10.1002/mds.1069</idno><idno type="ArticleID">MDS1069</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term><term>apomorphine</term><term>diagnosis</term><term>levodopa</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Alberto Albanese MD</name><affiliations><json:string>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</json:string></affiliations></json:item><json:item><name>Ubaldo Bonuccelli MD</name><affiliations><json:string>Clinica Neurologica, Università di Pisa, Pisa, Italy</json:string></affiliations></json:item><json:item><name>Christine Brefel MD</name><affiliations><json:string>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</json:string></affiliations></json:item><json:item><name>K. Ray Chaudhuri MD, FRCP</name><affiliations><json:string>Department of Neurology, King's College Hospital, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Carlo Colosimo MD</name><affiliations><json:string>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</json:string></affiliations></json:item><json:item><name>Tobias Eichhorn MD</name><affiliations><json:string>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</json:string></affiliations></json:item><json:item><name>Eldad Melamed MD</name><affiliations><json:string>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</json:string></affiliations></json:item><json:item><name>Pierre Pollak MD</name><affiliations><json:string>Service de Neurologie, Université J. Fourier, Grenoble, France</json:string></affiliations></json:item><json:item><name>Teus Van Laar MD, PhD</name><affiliations><json:string>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</json:string></affiliations></json:item><json:item><name>Mario Zappia MD</name><affiliations><json:string>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>apomorphine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>diagnosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item></subject><articleId><json:string>MDS1069</json:string></articleId><language><json:string>eng</json:string></language><abstract>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.</abstract><qualityIndicators><score>4.703</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>844</abstractCharCount><pdfWordCount>3323</pdfWordCount><pdfCharCount>22328</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>115</abstractWordCount></qualityIndicators><title>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>16</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>5</total><last>201</last><first>197</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1002/mds.1069</json:string></doi><id>3638D905253CBADE5F33953F6B488F265CEAEE7E</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/3638D905253CBADE5F33953F6B488F265CEAEE7E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/3638D905253CBADE5F33953F6B488F265CEAEE7E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3638D905253CBADE5F33953F6B488F265CEAEE7E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2001</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><author><persName><forename type="first">Alberto</forename><surname>Albanese</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Istituto Nazionale Neurologico, Via G. Celoria, 11, I‐20133 Milano, Italy.</p></note><affiliation>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</affiliation></author><author><persName><forename type="first">Ubaldo</forename><surname>Bonuccelli</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinica Neurologica, Università di Pisa, Pisa, Italy</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Brefel</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</affiliation></author><author><persName><forename type="first">K. Ray</forename><surname>Chaudhuri</surname></persName><roleName type="degree">MD, FRCP</roleName><affiliation>Department of Neurology, King's College Hospital, London, United Kingdom</affiliation></author><author><persName><forename type="first">Carlo</forename><surname>Colosimo</surname></persName><roleName type="degree">MD</roleName><affiliation>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</affiliation></author><author><persName><forename type="first">Tobias</forename><surname>Eichhorn</surname></persName><roleName type="degree">MD</roleName><affiliation>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</affiliation></author><author><persName><forename type="first">Eldad</forename><surname>Melamed</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Pollak</surname></persName><roleName type="degree">MD</roleName><affiliation>Service de Neurologie, Université J. Fourier, Grenoble, France</affiliation></author><author><persName><forename type="first">Teus</forename><surname>Van Laar</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</affiliation></author><author><persName><forename type="first">Mario</forename><surname>Zappia</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-03"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="201">201</biblScope></imprint></monogr><idno type="istex">3638D905253CBADE5F33953F6B488F265CEAEE7E</idno><idno type="DOI">10.1002/mds.1069</idno><idno type="ArticleID">MDS1069</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>apomorphine</term></item><item><term>levodopa</term></item><item><term>diagnosis</term></item><item><term>Parkinson disease</term></item><item><term>treatment</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-09-09">Received</change><change when="2000-10-01">Registration</change><change when="2001-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/3638D905253CBADE5F33953F6B488F265CEAEE7E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v16:2</doi><numberingGroup><numbering type="journalVolume" number="16">16</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2001-03">March 2001</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="4" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.1069</doi><idGroup><id type="unit" value="MDS1069"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2001 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2000-09-09"></event><event type="manuscriptAccepted" date="2000-10-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2001-03-12"></event><event type="firstOnline" date="2001-03-12"></event><event type="publishedOnlineFinalForm" date="2001-03-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">197</numbering><numbering type="pageLast">201</numbering></numberingGroup><correspondenceTo>Istituto Nazionale Neurologico, Via G. Celoria, 11, I‐20133 Milano, Italy.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1069.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="45"></count><count type="wordTotal" number="3182"></count></countGroup><titleGroup><title type="main" xml:lang="en">Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title><title type="short" xml:lang="en">Dopaminergic Challenge in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Alberto</givenNames><familyName>Albanese</familyName><degrees>MD</degrees></personName><contactDetails><email>alberto.albanese@rm.unicatt.it</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Ubaldo</givenNames><familyName>Bonuccelli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Christine</givenNames><familyName>Brefel</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>K. Ray</givenNames><familyName>Chaudhuri</familyName><degrees>MD, FRCP</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Carlo</givenNames><familyName>Colosimo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Tobias</givenNames><familyName>Eichhorn</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Eldad</givenNames><familyName>Melamed</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Pierre</givenNames><familyName>Pollak</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Teus</givenNames><familyName>Van Laar</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Mario</givenNames><familyName>Zappia</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Clinica Neurologica, Università di Pisa, Pisa, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, King's College Hospital, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="IT" type="organization"><unparsedAffiliation>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="DE" type="organization"><unparsedAffiliation>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="FR" type="organization"><unparsedAffiliation>Service de Neurologie, Université J. Fourier, Grenoble, France</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="NL" type="organization"><unparsedAffiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="IT" type="organization"><unparsedAffiliation>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">apomorphine</keyword><keyword xml:id="kwd2">levodopa</keyword><keyword xml:id="kwd3">diagnosis</keyword><keyword xml:id="kwd4">Parkinson disease</keyword><keyword xml:id="kwd5">treatment</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dopaminergic Challenge in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Alberto</namePart><namePart type="family">Albanese</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Istituto di Neurologia, Università Cattolica, and Istituto Nazionale Neurologico, Milano, Italy</affiliation><description>Correspondence: Istituto Nazionale Neurologico, Via G. Celoria, 11, I‐20133 Milano, Italy.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ubaldo</namePart><namePart type="family">Bonuccelli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinica Neurologica, Università di Pisa, Pisa, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Médical et Clinique, INSERM U455, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K. Ray</namePart><namePart type="family">Chaudhuri</namePart><namePart type="termsOfAddress">MD, FRCP</namePart><affiliation>Department of Neurology, King's College Hospital, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carlo</namePart><namePart type="family">Colosimo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Dipartimento di Scienze Neurologiche, Università La Sapienza, Roma, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tobias</namePart><namePart type="family">Eichhorn</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Klinik für Neurologie, Zentrum für Nervenheilkunde, Philipps‐Universität Marburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eldad</namePart><namePart type="family">Melamed</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Beilinson Medical Centre, Sackler Medical School, Tel‐Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Pollak</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de Neurologie, Université J. Fourier, Grenoble, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Teus</namePart><namePart type="family">Van Laar</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mario</namePart><namePart type="family">Zappia</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinica Neurologica, Università di Catanzaro, Catanzaro, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2001-03</dateIssued><dateCaptured encoding="w3cdtf">2000-09-09</dateCaptured><dateValid encoding="w3cdtf">2000-10-01</dateValid><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">45</extent><extent unit="words">3182</extent></physicalDescription><abstract lang="en">Available evidence on the practice of acute pharmacological challenge tests in parkinsonian patients was reviewed by a committee of experts, which achieved a general consensus. The published data deal mainly with the acute administration of levodopa and apomorphine in Parkinson's disease. Such challenge may serve different purposes, e.g., research, diagnosis, or tailoring of treatment. Unique protocols describing the clinical setting and practice parameters are not available. The present paper describes the scientific background and supplies practical guidelines, whenever possible, to perform and evaluate acute challenge tests in parkinsonian syndromes. With the appropriate indication and setting, acute challenge tests are useful in diagnosis and therapy of Parkinson's disease and related disorders. © 2001 Movement Disorder Society.</abstract><subject lang="en"><genre>Keywords</genre><topic>apomorphine</topic><topic>levodopa</topic><topic>diagnosis</topic><topic>Parkinson disease</topic><topic>treatment</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>197</start><end>201</end><total>5</total></extent></part></relatedItem><identifier type="istex">3638D905253CBADE5F33953F6B488F265CEAEE7E</identifier><identifier type="DOI">10.1002/mds.1069</identifier><identifier type="ArticleID">MDS1069</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2001 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002925 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002925 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:3638D905253CBADE5F33953F6B488F265CEAEE7E
|texte= Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |